Sanofi SA Sponsored ADR (EURONEXT:SAN) beat Q2 estimates with stronger EPS, operating income, sales and free cash flow, then announced a tighter R&D focus and portfolio review that may cut programs (amlitelimab, itepekimab, balinatunfib) to prioritize high‑science, high‑need projects.
Previous Week Recap
- Sanofi SA Sponsored ADR: Strong Q2 Earnings: Sanofi SA Sponsored ADR (SAN) Q2: business EPS €2.09 vs €1.90 expected, operating income €3.29B vs €2.97B, net sales €11.60B vs €10.85B, free cash flow €2.67B
- Sanofi SA to Tighten R&D Portfolio Review: Sanofi SA (SAN) will tighten R&D, review its portfolio and may stop programs or assets (e.g., amlitelimab, itepekimab, balinatunfib). Focus on projects with strong science and high unmet need.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.